



## Centre for Tropical Medicine and Global Health

Nuffield Department of Medicine  
Nuffield Department of Medicine Research Building  
University of Oxford  
Old Road Campus, Roosevelt Drive  
Headington  
OXFORD  
OX3 7FZ

Cambridge East REC  
E-submission

14 April 2021

Dear Sir or Madam

**Trial:** Randomised evaluation of Covid-19 therapy (RECOVERY)  
**EudraCT:** 2020-001113-21  
**IRAS:** 281712  
**REC ref:** 20/EE/0101

Please find enclosed an application for an expedited authorisation of a substantial amendment for the above trial. We are applying for this amendment for the following reasons:

1. On 4<sup>th</sup> March 2021 the Data Monitoring Committee recommended that recruitment to the colchicine comparison be stopped, because of futility. Recruitment was therefore stopped on 5<sup>th</sup> March 2021. Analyses are ongoing and will be submitted for publication in the next few weeks.
2. The trial steering committee has determined that sufficient participants have been recruited to the aspirin comparison to reliably identify a 12.5% reduction in mortality. Recruitment to this comparison was therefore stopped on 21<sup>st</sup> March. Follow-up is ongoing.
3. The removal of aspirin and colchicine from the trial means that our international sites do not have any treatments available to recruit to. We therefore wish to add some treatments that have been recommended by the COVID-19 Therapeutics Advisory Panel to the protocol which we will start at our international sites. These are infliximab and – among people at higher risk of death – high-dose corticosteroids (described in the enclosed justification). We do not wish to introduce them in the UK yet because we have other immunomodulatory therapies already in the protocol (dimethyl fumarate, baricitinib) and the number of cases (hence recruitment) is falling rapidly. However, we would ask the REC to review this amendment in order to keep a unified international protocol as you have kindly done in the past. If and when we are in a position to start recruitment to these comparisons in the UK we would submit a further amendment.

We would like to request that this amendment is **category A**, as per the amendment tool.

I believe all the necessary documentation required for this submission is attached and look forward to hearing the outcome.

Please let us know if you require any further information.





## Centre for Tropical Medicine and Global Health

Nuffield Department of Medicine  
Nuffield Department of Medicine Research Building  
University of Oxford  
Old Road Campus, Roosevelt Drive  
Headington  
OXFORD  
OX3 7FZ

Yours faithfully

A handwritten signature in blue ink, appearing to read 'Peter Horby', with a long horizontal flourish at the end.

**Professor Peter W. Horby**

BSc MSc MBBS FRCP FFPH PhD  
Chief Investigator, RECOVERY Trial  
Professor of Emerging Infectious Diseases and Global Health

Attached files:

1. RECOVERY Protocol V15.0 (tracked and clean)
2. RECOVERY PIS/ICF (adult) V13.0 (tracked and clean)
3. Infliximab SmPC
4. Prednisolone SmPC (NB SmPCs for other corticosteroids previously submitted as already in protocol)
5. Letter confirming sponsor approval
6. Amendment Tool for SA17
7. Justification for SA17

